

Brain Ischemia - Pipeline Review, H1 2017

<https://marketpublishers.com/r/BA2BF217D83EN.html>

Date: May 2017

Pages: 54

Price: US\$ 2,000.00 (Single User License)

ID: BA2BF217D83EN

Abstracts

Brain Ischemia - Pipeline Review, H1 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Brain Ischemia - Pipeline Review, H1 2017, provides an overview of the Brain Ischemia (Central Nervous System) pipeline landscape.

Brain ischemia is a stroke is when the blood supply to any part of the brain is interrupted, resulting in tissue death and loss of brain function. The most common cause of stroke is atherosclerosis. Symptoms include loss of movement of body area, weakness, numbness, decreased vision, loss of memory, vertigo, loss of coordination and urinary incontinence. Treatment includes analgesics to control severe headache, anti-hypertensive medication to control high blood pressure and anti-platelet agents.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Brain Ischemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Brain Ischemia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Brain Ischemia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Brain Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by

Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 10 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 7 molecules, respectively.

Brain Ischemia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Brain Ischemia (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Brain Ischemia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Brain Ischemia (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Brain Ischemia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of

administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Brain Ischemia (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Brain Ischemia (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Brain Ischemia (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Brain Ischemia - Overview
- Brain Ischemia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Brain Ischemia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Brain Ischemia - Companies Involved in Therapeutics Development
- CohBar Inc
- Lixte Biotechnology Holdings Inc
- NeuroNascent Inc
- NeurOp Inc
- NoNO Inc
- Prolong Pharmaceuticals LLC
- Spectrum Pharmaceuticals Inc
- Vect-Horus SAS
- Brain Ischemia - Drug Profiles
- 2-CCPA - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- AB-002 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- ADA-409 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- CIDEM-161 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
CIGB-845 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit SRC-ND2 Interaction for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Humanin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LAU-0901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LB-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-10679 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
phycocyanobilin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Activate GDNF for Brain Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sanguinate - Drug Profile
Product Description
Mechanism Of Action

R&D Progress

Small Molecules for Brain Ischemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Gpr17 for Brain Ischemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize TRPM7 for Oncology, Ophthalmology, Cardiovascular and Central nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SPI-1620 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Ischemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VHN-439 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Brain Ischemia - Dormant Projects

Brain Ischemia - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Brain Ischemia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Brain Ischemia - Pipeline by CohBar Inc, H1 2017
Brain Ischemia - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
Brain Ischemia - Pipeline by NeuroNascent Inc, H1 2017
Brain Ischemia - Pipeline by NeurOp Inc, H1 2017
Brain Ischemia - Pipeline by NoNO Inc, H1 2017
Brain Ischemia - Pipeline by Prolong Pharmaceuticals LLC, H1 2017
Brain Ischemia - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017
Brain Ischemia - Pipeline by Vect-Horus SAS, H1 2017
Brain Ischemia - Dormant Projects, H1 2017
Brain Ischemia - Discontinued Products, H1 2017

List Of Figures

LIST OF FIGURES

Number of Products under Development for Brain Ischemia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

COMPANIES MENTIONED

CohBar Inc
Lixte Biotechnology Holdings Inc
NeuroNascent Inc
NeurOp Inc
NoNO Inc
Prolong Pharmaceuticals LLC
Spectrum Pharmaceuticals Inc
Vect-Horus SAS

I would like to order

Product name: Brain Ischemia - Pipeline Review, H1 2017

Product link: <https://marketpublishers.com/r/BA2BF217D83EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BA2BF217D83EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970